First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure : vimarsana.com

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...

Related Keywords

University Of North Carolina , North Carolina , United States , Berlin , Germany , Research Triangle Park , Edinburgh , City Of , United Kingdom , Gipuzkoa , Pais Vasco , Spain , Scotland , American , Spanish , Rogerj Hajjar , Josh Grieger , Phil Mcnamara , R Jude Samulski , Christian Rommel , Timothyd Henry , Steering Committee Member , Trademark Office , Manufacturing Organization , Technology Park , Asklepios Biopharmaceutical Inc , Drug Administration , York Heart Association , Contract Development , Linkedin , Bayer Ag , American Heart Association , Global Public Health Burden Of Heart Failure , Centers For Disease , Head Of Research , Spanish Agency For Medicines , New York Heart Association , Asklepios Biopharmaceutical , Inhibition Therapy , Principal Investigator , Steering Committee , Heart Failure Awareness Week , Scientific Chair , Executive Committee , Pharmaceuticals Division , Viralgen Vector Core , Six Minute Walk Test , Current Good Manufacturing Practice , Chief Technical Officer Josh Grieger , Gipuzkoa Science , Scientific Park , Spanish Agency , Medical Devices , United States Food , United States Patent , Intracoronary Gene Therapy , Subjects With Non Ischemic , Accessed February , Treasure Island , Statpearls Publishing , Disease Control , American Heart , Public Health Burden , Card Fail , Continuous Harvest , Vector From , Culture Media , Bio Media Contact , Global Media Contact , Nuria Aiguabella Font ,